Ex vivo tumor testing platform for predicting clinical response to platinum-based therapy in patients with high grade serous ovarian cancer

被引：0
|
作者：
Ottevanger, P. B.
Kroep, Judith R.
van Persijn-van Meerten, Els L.
van Altena, Anne M.
de Kroon, Cornelis
Ceton, Lieke J.
Montero, Marta G.
van der Meer, Donny J.
Vader, Willemijn
机构：
[1] Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands
[2] Leiden Univ, Med Ctr, Leiden, Netherlands
[3] Leiden Univ, Med Ctr, Dept Radiol, Leiden, Netherlands
[4] VitroScan BV, Leiden, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5563
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Histopathology and proteomics are synergistic for high-grade serous ovarian cancer platinum response prediction
    Kilim, Oz
    Olar, Alex
    Biricz, Andras
    Madaras, Lilla
    Pollner, Peter
    Szallasi, Zoltan
    Sztupinszki, Zsofia
    Csabai, Istvan
    NPJ PRECISION ONCOLOGY, 2025, 9 (01)
  • [32] DETECTION RATES OF HIGH GRADE SEROUS OVARIAN CANCER USING A CLINICAL NON-INVASIVE PRENATAL TESTING PLATFORM: POTENTIAL FOR OVARIAN CANCER SCREENING
    Cohen, P.
    Flowers, N.
    Tong, S.
    Hannan, N.
    Pertile, M.
    Hui, L.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 663 - 663
  • [33] Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian Cancer
    Andrikopoulou, Angeliki
    Theofanakis, Charalampos
    Markellos, Christos
    Kaparelou, Maria
    Koutsoukos, Konstantinos
    Apostolidou, Kleoniki
    Thomakos, Nikolaos
    Haidopoulos, Dimitrios
    Rodolakis, Alexandros
    Dimopoulos, Meletios-Athanasios
    Zagouri, Flora
    Liontos, Michalis
    CANCERS, 2023, 15 (13)
  • [34] Decoding tumor-induced senescence: ex vivo insights from neoadjuvant chemotherapy in high-grade serous ovarian cancer
    Giglioni, Claudia
    Barsanti, Federica
    Orlandi, Gretha
    Magherini, Francesca
    Taddei, Maria Letizia
    Farsi, Elisa
    Fambrini, Massimiliano
    Sorbi, Flavia
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A341 - A342
  • [35] Tumor Growth Rate Estimates Are Independently Predictive of Therapy Response and Survival in Recurrent High-Grade Serous Ovarian Cancer Patients
    Bartl, Thomas
    Karacs, Jasmine
    Kreuzinger, Caroline
    Pfaffinger, Stephanie
    Kendler, Jonatan
    Ciocsirescu, Cristina
    Wolf, Andrea
    Reinthaller, Alexander
    Meyer, Elias
    Brandstetter, Maximilian
    Postl, Magdalena
    Langthaler, Eva
    Braicu, Elena
    Vergote, Ignace
    Cunnea, Paula
    Gourley, Charlie
    Schmitt, Wolfgang D.
    Cacsire Castillo-Tong, Dan
    Christoph, Grimm
    CANCERS, 2021, 13 (05) : 1 - 14
  • [36] DNA damage response deficiency signature predicts response to platinum-based therapy in ovarian cancer
    Hill, L. A.
    Mulligan, J. M.
    Deharo, S.
    Keating, K. E.
    McDyer, F. A.
    Davison, T. S.
    Gourley, C.
    Harkin, D. P.
    Kennedy, R. D.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S196 - S196
  • [37] High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation
    Gorodnova, Tatiana V.
    Sokolenko, Anna P.
    Ivantsov, Alexandr O.
    Iyevleva, Aglaya G.
    Suspitsin, Evgeny N.
    Aleksakhina, Svetlana N.
    Yanus, Grigory A.
    Togo, Alexandr V.
    Maximov, Sergey Ya.
    Imyanitov, Evgeny N.
    CANCER LETTERS, 2015, 369 (02) : 363 - 367
  • [38] 3D organoid models for predicting drug response in platinum-sensitive, high-grade serous ovarian cancer
    Mackay, Helen
    Gien, Lilian
    Buzina, Alla
    Schormann, Wiebke
    Andrews, David
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S219 - S219
  • [39] USE OF 3D ORGANOTYPIC MODELS TO ASSESS HETEROGENEITY IN RESPONSE TO PLATINUM THERAPY IN HIGH GRADE SEROUS OVARIAN CANCER
    Nixon, K.
    Curry, E.
    Wulandari, R.
    Morera-Albert, C.
    Cunnea, P.
    Fotopoulou, C.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A145 - A145
  • [40] Ex vivo treatment in high grade serous ovarian cancer demonstrates the benefit of EZH2 inhibition in combination with standard therapy
    Vo, Ha V.
    Zeng, Qing
    Barbie, David A.
    Gokhale, Prafulla C.
    Adams, Elizabeth
    Paweletz, Cloud P.
    Ivanova, Elena
    CANCER RESEARCH, 2022, 82 (12)
12345